MolecularMD
Portland
About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly targeted cancer therapies. MolecularMD’s assays incorporate both gold-standard and innovative technologies to provide highly sensitive, standardized, reliable results that support clinical development, regulatory approval, and commercialization of novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Brian Druker, director of the Knight Cancer Center at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation and Upstate Biotechnology.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $14.0M
- Funding stage: M&A
- Last round: Series Unknown (Feb 2017)
- Website: molecularmd.com
- Phone: 1(877)459-4979
Industries & Categories
Biotechnology, Health Diagnostics, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/molecularmd-138887 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.